Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CCR4 | P51679 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2762297 | 0.90 | KDR (0.52) | KDRBRAFMAPK14TNNI3KMET | |
| SCHEMBL2763291 | 0.88 | KDR (0.50) | KDRBRAFMAPK14TNNI3KMET | |
| SCHEMBL2763083 | 0.87 | KDR (0.52) | KDRBRAFMAPK14TNNI3KEPHX2 | |
| SCHEMBL2763212 | 0.87 | KDR (0.52) | KDRBRAFMAPK14TNNI3KMET | |
| SCHEMBL2762478 | 0.85 | KDR (0.68) | KDRBRAFMAPK14TNNI3KMET | |
| SCHEMBL2762782 | 0.83 | KDR (0.55) | KDRBRAFMAPK14TNNI3K | |
| SCHEMBL2762807 | 0.83 | KDR (0.48) | KDRBRAFMAPK14TNNI3KMET | |
| SCHEMBL2763105 | 0.82 | KDR (0.67) | KDRBRAF | |
| SCHEMBL2762816 | 0.82 | BRAF (0.49) | KDRBRAFMAPK14TNNI3KMET | |
| SCHEMBL2762754 | 0.82 | BRAF (0.63) | KDRBRAFMAPK14TNNI3K |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8080552-B2 | Pyrimidyl derivatives as protein kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2011-12-20 | — | — | US | claimed |
| EP-2102173-B1 | PYRIMIDYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-10-20 | — | — | EP | claimed |
| US-20100041684-A1 | PYRIMIDYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | HOFFMANN-LA ROCHE, INC. | 2010-02-18 | — | — | US | claimed |
| EP-2102173-A1 | PYRIMIDYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2009-09-23 | — | — | EP | claimed |
| WO-2008077548-A1 | PYRIMIDYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-03 | — | — | WO | claimed |
| US-8080552-B2 | Pyrimidyl derivatives as protein kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2011-12-20 | — | — | US | disclosed |
| EP-2102173-B1 | PYRIMIDYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-10-20 | — | — | EP | disclosed |
| US-20100041684-A1 | PYRIMIDYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | HOFFMANN-LA ROCHE, INC. | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041684-A1 | PYRIMIDYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | MAP3K5, MAP3K1, MAP4K2 | KDR 1270/4885BRAF 47/4885MAPK14 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.